Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Cash from Operations (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Cash from Operations for 10 consecutive years, with 31129000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations rose 797.02% to 31129000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 67992000.0 through Dec 2025, up 267.22% year-over-year, with the annual reading at 67992000.0 for FY2025, 267.22% up from the prior year.
  • Cash from Operations for Q4 2025 was 31129000.0 at Akebia Therapeutics, up from 28105000.0 in the prior quarter.
  • The five-year high for Cash from Operations was 33805000.0 in Q3 2022, with the low at 70746000.0 in Q1 2021.
  • Average Cash from Operations over 5 years is 16108500.0, with a median of 11826500.0 recorded in 2024.
  • The sharpest move saw Cash from Operations plummeted 377.38% in 2024, then soared 797.02% in 2025.
  • Over 5 years, Cash from Operations stood at 62808000.0 in 2021, then increased by 12.94% to 54679000.0 in 2022, then skyrocketed by 95.78% to 2308000.0 in 2023, then tumbled by 93.5% to 4466000.0 in 2024, then skyrocketed by 797.02% to 31129000.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 31129000.0, 28105000.0, and 22345000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.